15 June 2026
UAE
Testvox FZCO
Fifth Floor 9WC Dubai Airport Freezone
FDA Cybersecurity: What You Need to Know
17 June 2026
9:33 MIN Read time 
BY
Divya Prakash
The medical device industry is currently navigating one of its most significant transformations since the advent of software based diagnostics. For a long time, cybersecurity was treated as a secondary concern, a technical hurdle managed by IT departments rather than a core clinical safety requirement. However, as hospital systems face an onslaught of ransomware attacks and “zero day” vulnerabilities, the FDA has made it clear that a device cannot be considered safe if it is not secure.
Understanding the FDA’s stance on cybersecurity is no longer just for the compliance team; it is essential for every stakeholder in the product development lifecycle. If you are bringing a connected device to market today, you are essentially building a specialized computer that lives in a hostile digital environment. This blog dives into the critical updates, the terminology that defines the current landscape, and the ongoing responsibilities that remain long after your device hits the shelves.
FDA’s Cybersecurity Guidance Evolution: 2014 to 2023
To understand where we are, we have to look at how we got here. The FDA’s journey with cybersecurity has been a decade long climb from “suggested best practices” to “mandatory requirements.”
In 2014, the FDA released its first major premarket cybersecurity guidance. At the time, it was relatively high level. It focused on the idea that manufacturers should consider security during design and provide documentation to the agency. It was a wake up call, but it lacked the teeth to force industry wide standardization.
By 2018, as the “Internet of Medical Things” (IoMT) exploded, the agency issued a draft update that introduced the concept of “tiers” based on risk. This was the first time we saw a formal push toward the “Secure by Design” philosophy. However, the biggest turning point came in late 2022 and early 2023.
Congress granted the FDA explicit statutory authority through Section 524B of the FD&C Act. This changed everything. Cybersecurity moved from being a guidance recommendation to a legal requirement for any “cyber device.” The final 2023 guidance, titled “Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions,” is now the gold standard. It mandates comprehensive documentation, including Software Bills of Materials (SBOM) and formal vulnerability disclosure plans, effectively closing the door on the era of voluntary security.
Key Terminology Every Medical Device Maker Must Understand
Regulatory language can feel like a labyrinth, but mastering a few key terms will help you speak the same language as your FDA reviewer.
- Cyber Device: According to the new law, a cyber device is any device that includes software validated by or on behalf of the sponsor, has the ability to connect to the internet, and could be vulnerable to cybersecurity threats. This definition is intentionally broad to cover everything from wearable sensors to massive imaging systems.
- SBOM (Software Bill of Materials): Think of this as the “nutrition label” for your software. It is a nested list of every ingredient in your code, including open source libraries, third party drivers, and commercial software components. If a new exploit is found in a common library, the SBOM tells the FDA and the user exactly which devices are at risk.
- Total Product Lifecycle (TPLC): The FDA no longer looks at security as a “point in time” event. TPLC means you are responsible for security from the very first design sketch until the device is officially decommissioned and removed from service.
- Vulnerability Disclosure: This is a formal process where you provide a way for security researchers or users to report bugs to you. It requires a “coordinated” approach, ensuring that you fix the hole before the details are made public.
How FDA Evaluates Cybersecurity Risk in Submissions
The FDA does not expect your device to be “unhackable” because they know that is an impossible standard. Instead, they evaluate your submission based on the adequacy of your risk management.
When a reviewer looks at your file, they are looking for a “Closed Loop” logic. They want to see your Threat Model, which is essentially a document where you “think like a hacker.” You identify every possible way someone could attack your device, from physical USB ports to wireless Bluetooth connections.
The reviewer then looks at your Security Risk Assessment. You must demonstrate that you have evaluated how a security breach could lead to clinical harm. For example, if a hacker changes the dosage on an infusion pump, that is a direct safety issue. If they merely steal a patient’s name, that is a privacy issue. While the FDA cares about both, their primary mandate is the prevention of patient harm.
Finally, they look for Verification and Validation. This is the proof. You must provide evidence that your security controls actually work. This often includes penetration testing results where ethical hackers tried (and hopefully failed) to break into your system.
Post-Approval Cybersecurity Obligations You Can’t Ignore
The day you receive your FDA clearance is not the finish line; it is just the beginning of a new phase of responsibility. Under Section 524B, manufacturers have ongoing obligations that are now legally enforceable.
You are required to have a plan to monitor, identify, and address postmarket vulnerabilities. This means you must actively “hunt” for threats. You cannot wait for a hospital to tell you they were hacked. You should be monitoring databases of known vulnerabilities and checking if any of your SBOM components have been compromised.
Furthermore, you must provide “Reasonable Assurance” that the device remains secure through regular updates and patches. The FDA expects you to have a mechanism to push these updates to devices in the field quickly. If a “Critical” vulnerability is found, you are expected to communicate this to the user base immediately and provide a timeline for a fix. This “Postmarket Management Plan” is now a required part of your initial submission, and failing to follow it after approval could lead to enforcement actions or recalls.
The Challenge of Legacy Devices
One of the most complex areas of the new regulation involves “Legacy Devices.” These are products that were cleared years ago, before modern security standards existed. While Section 524B primarily targets new submissions, the FDA has made it clear that if you submit a “change” or a “modification” to an old device (a 510k supplement), you may be required to bring the entire system up to current cybersecurity standards.
As noted in recent industry discussions, particularly regarding Section 524B, the FDA is looking at the “ecosystem.” If your legacy device connects to a modern network, it could be a “weak link” that allows an attacker to pivot into more sensitive areas of a hospital. Manufacturers must decide whether to invest in “refactoring” the security of these old devices or to begin the process of phasing them out in favor of “Secure by Design” next generation models.
Building a Culture of Security
Ultimately, meeting FDA requirements is not just about filling out forms; it is about a fundamental shift in corporate culture. Cybersecurity cannot be an “add on” at the end of development. It must be integrated into the Quality Management System (QMS).
Every engineer should understand the basics of secure coding. Every product manager should understand the impact of a security breach on the brand’s reputation. When security is part of the DNA of a company, the FDA submission process becomes significantly smoother. You aren’t “inventing” documentation to satisfy a reviewer; you are simply sharing the rigorous work you have already done to protect the patients who rely on your technology.
Final Thoughts: Transparency as a Competitive Advantage
While the new FDA cybersecurity requirements may seem like a heavy burden, they actually offer a massive opportunity. In a world where healthcare providers are increasingly terrified of digital threats, being able to prove that your device is “FDA Secure” is a powerful competitive advantage.
Transparency is the new currency of trust. By providing a clear SBOM, a robust threat model, and a proactive patching plan, you are telling your customers that you take their safety seriously. The FDA is setting a high bar, but it is a bar that ensures the medical devices of tomorrow are as resilient as they are innovative. The manufacturers who embrace these changes now will be the ones who lead the industry into a more secure and connected future.
15 June 2026
28 April 2026
29 April 2026
ABOUT TESTVOX
Testvox is a software testing company help your product reach its full potential. Get full cycle testing for your mobile and web applications while ensuring all quality assurance standards are met... Read More
100+
Applications
Assured
Assured
5 Star Rating
5 Star Rating
“By participating in our release lifecycle, Testvox's standard QA process has helped us to launch quality products faster.”
Rima Hudaifa
Manager | Cadvil
Manager | Cadvil
